JNJosep Fr. Nomdedeu

Josep Fr. Nomdedeu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Josep Fr. Nomdedeu has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Measurable Residual Disease in IDH ‐Mutated AML : Identifying a Clinically Relevant Threshold for IDH Mutation Monitoring

    by Guillermo Ramil, Elena Bussaglia, Helena Castellet, Guadalupe Oñate, Ana Garrido, Maite Carricondo, Anna Giné‐Vilalta, Nuria González, Paula San‐José, Rodrigo Martino, et al.

    Background: Isocitrate dehydrogenase ( IDH ) mutations are recurrent in acute myeloid leukemia (AML) and represent promising targets for measurable residual disease (MRD) monitoring. However, clinically validated strategies for IDH ‐based MRD assessment remain lacking. Methods: We evaluated the analytical performance and clinical utility of droplet digital PCR (ddPCR) for IDH mutation monitoring in a single‐center cohort of patients with IDH ‐mutated AML treated with curative intent. Healthy controls were included to characterize low‐level background signals and identify a clinical threshold. Results: ddPCR showed robust analytical performance, with a limit of detection of 0.01% variant allele frequency (VAF) and strong concordance with NGS. Low‐level IDH mutation signals were frequently detected in healthy individuals and in patients in remission. We identified 0.2% VAF as a candidate threshold for clinically relevant IDH MRD. Using this cutoff, post‐treatment detectable IDH MRD was associated with a higher 2‐year cumulative incidence of relapse (63.6% vs. 20%; p = 0.019) and inferior overall survival (70.6% vs. 92.9%; p = 0.04). Among patients negative by multiparameter flow cytometry, ddPCR identified residual IDH‐ mutated clones in 56% of cases, who showed higher relapse rates than double‐negative patients (50% vs. 0%; p = 0.031). Conclusions: A 0.2% VAF threshold was associated with clinically distinct outcomes and may provide a useful framework for IDH ‐based MRD assessment in AML.

  • Rapid molecular screening of adult AML : Experience from the Spanish CETLAM cooperative group

    by Helena Castellet, Anna Giné‐Vilalta, Marta Pratcorona, Guillermo Ramil, Guadalupe Oñate, Francesca Guijarro, Sandra Castaño‐Díez, Montserrat Arnan, Helena Pomares, Mar Tormo, et al.

    Summary: Genetic testing is essential for risk stratification and early therapeutic decision‐making in acute myeloid leukaemia (AML). While 2022 European LeukemiaNet (ELN) guidelines recommend a 3–5‐day turnaround time for key molecular markers, next‐generation sequencing (NGS) often extends to 15 days in clinical practice. In this study, we evaluated the first‐year results of a centralized rapid screening platform for 15 hospitals in the Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (CETLAM) cooperative group, modelled after the German‐Austrian Acute Myeloid Leukaemia Study Group (AMLSG) diagnostic strategy. We prospectively enrolled 211 consecutive adult patients with de novo AML. A centralized laboratory performed nucleic acid purification, biobanking and high‐priority molecular analysis including nucleophosmin 1 ( NPM1 ), Fms‐like tyrosine kinase 3 ( FLT3 ‐ITD/TKD), CCAAT enhancer binding protein alpha ( CEBPA ), isocitrate dehydrogenase 1 and 2 ( IDH1/2 ), lysine methyltransferase 2A ( KMT2A ‐PTD), upstream binding transcription factor ( UBTF ‐TD) and 10 key fusions using polymerase chain reaction (PCR) and capillary electrophoresis. Results were compared with local NGS and cytogenetics to assess diagnostic accuracy and ELN risk reclassification. The mean analytical turnaround time was 3–4 days for high‐priority mutations and 7 days for gene fusions. Initial rapid screening accurately identified 98% of favourable‐risk cases. However, 74% of patients initially classified as intermediate‐risk were reclassified as adverse‐risk upon integration of NGS and cytogenetics. This CETLAM initiative demonstrates that a centralized molecular platform is a feasible and reliable strategy for early risk stratification and therapeutic decision‐making in AML within a multicentre setting.


  • Open Access

    Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma

    by Rubén Osuna-Gómez, Jordi López-Pardo, Maria Mulet, Josep Nomdedéu, Elisabet Cantó, Rosa Ortin, Ángela Sánchez Cayuela, Ma Àngels Ortiz, Albert Guinart-Cuadra, Silvia Vidal

    Background/Objectives: CD38-targeting monoclonal antibodies isatuximab and daratumumab have revolutionized multiple myeloma (MM) treatment, but a deeper understanding of their distinct mechanisms is crucial for therapeutic optimization. Methods: We used flow cytometry to assess isatuximab and daratumumab binding competition in MM cell lines and patient-derived bone marrow cells. The dynamics of CD38 expression were evaluated at different time points before and after antibody-mediated removal. The effects of IMiDs (pomalidomide, lenalidomide) on CD38 expression and isatuximab-induced apoptosis, either alone or in combination with IMiDs, were also examined. Moreover, MM cell migration was assessed through CXCR4-mediated assays, and cell adhesion was evaluated via CD49d-dependent assays. Results: Isatuximab and daratumumab did not compete for CD38 binding, confirming distinct epitope recognition. Following depletion with either antibody, CD38 expression on the MM cell surface began to recover within 2 h, suggesting a dynamic regulation of CD38 availability. While daratumumab lacked direct apoptosis, isatuximab induced significant direct cell death. Pomalidomide enhanced isatuximab-induced apoptosis by increasing CD38 expression, whereas lenalidomide had no significant effect. Additionally, both antibodies effectively inhibited MM cell migration and significantly reduced cell adhesion. Conclusions: Their non-competitive binding and shared impact on cell dynamics suggest opportunities for optimizing treatment strategies through combinatorial or sequential approaches in MM therapy.


  • Open Access

    Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis

    by Matthew A. McLoughlin, Sruthi Cheloor Kovilakam, William G. Dunn, Muxin Gu, Jake Tobin, Yash Pershad, Nicholas Williams, Daniel Leongamornlert, Kevin Dawson, Laura Bond, et al.

    The mechanisms through which mutations in splicing factor genes drive clonal hematopoiesis (CH) and myeloid malignancies, and their close association with advanced age, remain poorly understood. Here we show that telomere maintenance plays an important role in this phenomenon. First, by studying 454,098 UK Biobank participants, we find that, unlike most CH subtypes, splicing-factor-mutant CH is more common in those with shorter genetically predicted telomeres, as is CH with mutations in PPM1D and the TERT gene promoter. We go on to show that telomere attrition becomes an instrument for clonal selection in advanced age, with splicing factor mutations ‘rescuing’ HSCs from critical telomere shortening. Our findings expose the lifelong influence of telomere maintenance on hematopoiesis and identify a potential shared mechanism through which different splicing factor mutations drive leukemogenesis. Understanding the mechanistic basis of these observations can open new therapeutic avenues against splicing-factor-mutant CH and hematological or other cancers.


  • Open Access

    SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions

    by Miguel A. Rubio, Sabina Cisa-Wieczorek, Ana Mozos, Helena Castellet, Elena Bussaglia, Maite Carricondo, María Isabel Hernández-Alvarez, Jorge Sierra, Josep F. Nomdedéu

    Increased WT1 mRNA levels are pervasive in acute myeloid leukemia (AML), and this marker has been used to assess the leukemic compartment size after chemotherapy or hematopoietic cell transplants. Little is known about the effects of WT1 on the leukemic cells and their targets. This work used data obtained from gene expression arrays performed on AML samples with high and low WT1 mRNA levels to pinpoint genes that WT1 can regulate. We singled out SGK1, which showed an inverse correlation between its mRNA levels and WT1 in leukemic cell lines and AML samples. In cellular models, forced expression of WT1 reduced mRNA and protein levels of SGK1. Furthermore, WT1 repressed the SGK1 promoter activity, and accordingly, WT1 knockdown showed an increased expression of SGK1. We also detected an inverse correlation between WT1 and SGK1 during leukemic cell-line differentiation. WT1 genetic knockdown displayed decreased cell viability under nutrient deprivation. By contrast, SGK1 knockdown or pharmacologic inhibition increased resistance to apoptosis in response to serum starvation, acting on cell cycle progression. The effects of SGK1 targeting in hematologic conditions merit further investigation.

  • Open Access

    CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases

    by Laura González-Guerrero, Helena Castellet, Clara Martínez, Nuria González, Francesca Guijarro, Natalia Lloveras, Marta Pratcorona, Ignasi Gich, Pau Berenguer-Molins, Júlia Perera-Bel, et al.

    CD200 is a glycoprotein that binds with its receptor CD200R, providing immunosuppressive signals to T and NK cells. CD200 is expressed by normal stem cells and progenitors committed to B-lymphopoiesis and myeloid development. CD200 biological relevance in acute leukemias is only partially understood. The study included a consecutive series of four hundred thirty-one patients with acute myeloid leukemia (AML). Immunophenotype was established by multiparametric flow cytometry, and the genetic diagnosis was performed by PCR-based methods and a targeted resequencing method covering 42 genes. 66% of AML patients expressed CD200 being significantly associated with CD34 reactivity. The frequency of CD200 positivity was higher in cases with core-binding factor genetic lesions such as RUNX1-RUNX1T1 (81.3%) fusions and CBFB-MHY11 (63.2%) rearrangements and also with biallelic CEBPA mutations (100%). The molecular AML group with the lowest CD200 reactivity (19.1%) corresponded to AML with NPM1 mutations. RNA seq showed no uniform pattern of infiltrating cells in CEBPA mutated AML. Deconvolution analysis may be used to assess the immunoregulatory mechanisms of AML. CD200 expression could help identify the more immature compartment and, combined with other markers, single out CEPA-mutated AML.


  • Measurable Residual Disease in UBTF‐TD Adult Acute Myeloid Leukemia

    by Helena Castellet, Guillermo Ramil, Maite Carricondo, Guadalupe Oñate, Ana Garrido, Alícia Artigas, Marta Pratcorona, Olga Salamero, Albert Cortés‐Bullich, Susana Vives, et al.

  • D816V KIT mutation induces mitochondrial morphologic and functional changes through BNIP3 downregulation in human myeloid cell lines ROSA and TF-1

    by Sabina Cisa-Wieczorek, Maria Isabel Hernández-Alvarez, Matilde Parreño, Juan P. Muñoz, Elena Bussaglia, Maite Carricondo, Jose Ubeda, Patrice Dubreuil, Antonio Zorzano, Fabienne Brenet, et al.


  • Open Access

    Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

    by Guadalupe Oñate, Ana Garrido, Montserrat Arnan, Helena Pomares, Ester Alonso, Mar Tormo, Marina Diaz-Beya, Susana Vives, Lurdes Zamora, Antonia Sampol, et al.

    Given the heterogeneity of acute myeloid leukemia patients, it is necessary to identify patients considered fit for intensive therapy but who will perform poorly, and in whom alternative approaches deserve investigation. We analyzed 1034 fit adults ≤70 years intensively treated between 2012 and 2022 in the CETLAM group. Young adults ( ≤ 60 years) presented higher remission rates and improved survival than older adults above that age (CR 79% vs. 73%; p = 0.03 and 4-yr OS 53% vs. 33%; p < 0.001). Remission and survival outcomes varied among different genetic subsets. An especially adverse genetic group included complex, monosomal karyotype, TP53 alterations (deleted/mutated), and MECOMr. Transplant feasibility in this very adverse risk group was low, and OS and EFS at 4 years were 14% and 12%, in contrast to 70% and 57% in the favorable group and 38% and 32% in all other patients. We integrated clinical and genetic data into the Intensive Chemotherapy Score for AML (ICSA) with 6-risk categories with significantly different remission rates and OS, validated in another cohort of 581 AML patients from a previous CETLAM protocol. In summary, we identified groups of fit patients that benefit differently from an intensive approach which may be helpful in future treatment decisions.


  • Open Access

    Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis

    by Marta Garcia Fasanella, Mozos, Javier Briones, Josep Nomdedéu, Novelli S

    Hairy Cell Leukemia (HCL) is a rare disorder characterized by splenomegaly, pancytopenia and proliferation with ‘hairy’ lymphocytes. Treatment is based on purine analogs and anti-CD20 antibodies, often resulting in significant adverse effects. This study analyzed 20 patients treated between 2009 and 2023, focusing on clinical characteristics, treatment response, complications and survival outcomes. Cladribine treatment achieved complete response in 77.8% of patients. The 5-year OS and PFS were 100% and 91.7%, respectively. Infections, pathogens such as herpes viruses and mycobacteria, were major complications, impacting 38% of patients. Severe skin reactions were noted in patients treated with cladribine. The study highlights cladribine’s effectiveness in inducing remission in HCL patients, pointing out the significant risk of infections and other adverse effects. Introducing targeted treatments like BRAF inhibitors provides promising alternatives, especially for resistant patients or those intolerant to purine analogs. Future strategies should focus on integrating targeted therapies to reduce treatment-related morbidity.